Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer

Fig. 2

a Flow cytometry gating strategy for detecting presence of human immune cells in blood of hu-CB-BRGS mice 16 weeks post engraftment and prior to tumor cell inoculation. b Percentage of human CD45+ cells in blood of hu-CB-BRGS mice plotted according to their distribution into treatment groups. c Tumor growth curves of MDA-MB-231 TNBC cell line xenograft tumors in hu-CB-BRGS mice at the indicated doses. Vehicle, Nivo, and RX-5902 arms were ended at Day 26 due to tumor size limits. Treatment was continued for the Combo arm due to their increased survival compared to the other groups. d Percent tumor growth inhibition (%TGI) for the indicated treatment groups. e Tumor growth rates for individual tumors in the indicated treatment groups over the duration of the treatment time. ****p < 0.0001; ***p < 0.001; *p < 0.05

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us